Chugai launches Tecentriq Intravenous Infusion 840 mg for treating TNBC
Category: #healthcare  By Mateen Dalal  Date: 2019-11-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Chugai launches Tecentriq Intravenous Infusion 840 mg for treating TNBC
  • This would be the first registered immune checkpoint inhibitor for treating PD-L1-positive TNBC in Japan.
     
  • The drug has also been listed on NHI reimbursement price list.

Chugai Pharmaceutical Co. Ltd., a Japanese drug manufacturer, has reportedly announced the launch of  Tecentriq® (atezolizumab) Intravenous Infusion 840 mg for treatment of PD-L1 positive TNBC. The drug has been listed on (NHI) reimbursement price list. Tecentriq 840 mg is an ideal formulation for treating PD-L1-positive and HER2-negative recurrent or breast cancer.

Dr. Osamu Okuda, Executive Vice President and Co-Head of Project & Lifecycle Management Unit, Chugai, said that in recent years, immune checkpoint inhibitor has changed the treatment landscape for several types of cancers. The company is pleased to offer Tecentriq as the first approved drug in the breast cancer field to patients suffering from PD-L1 positive TNBC.

Okuda added that TNBC is rapidly progressing and aggressive disease with restricted treatment options and huge unmet medical needs. The company would be engaged in providing information, aiming to benefit patients by offering this new cancer immunotherapy-based treatment for TNBC. 

Basically, Tecentriq is an immune checkpoint inhibitor that targets PD-L1; a protein expressed on tumor-infiltrating immune cells and tumor cells. PD-L1 stops T-cell activity by binding with B7.1 and PD-1 receptors on the T-cell surface.

By reducing PD-L1, Tecentriq could activate T-cells and improve immune response against cancer cells. The safety and efficacy of Tecentriq were examined in phase III IMpassion130 clinical trial. 

Reports state that, in Japan, around 86,500 women suffer from breast cancer each year. Out of this, 14,800 women die as a result of this disease. As one of the leading companies in the Japan’s oncology field, Chugai is dedicated to contributing to medical professionals and patients by presenting Tecentriq as a new treatment option and to improve access to medications.

Source Credit - https://www.chugai-pharm.co.jp/english/news/detail/20191127100000_671.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Tesla’s highly awaited cybertruck to face production delays until 2022
Tesla’s highly awaited cybertruck to face production delays until 2022
By Mateen Dalal

This EV pickup truck has an unorthodox design and boasts a formidable range of over 400 kms. The ...

French lawmakers approve a bill to deal with fourth wave of Coronavirus
French lawmakers approve a bill to deal with fourth wave of Coronavirus
By Mateen Dalal

The French parliament recently approved a bill that makes Covid-19 vaccination mandatory for health ...

China scraps WHO’s plans for 2nd phase of Covid-19 origin study
China scraps WHO’s plans for 2nd phase of Covid-19 origin study
By Mateen Dalal

The World Health Organization’s plan for a deeper probe into the origin of the coronavirus was...